Revuforj targets, binds, and blocks
Revuforj is a first-of-its-kind targeted treatment called a
menin inhibitor
![See less circle]()
If a KMT2A translocation was detected in your AML or ALL workup, and your disease has come back or has not improved after previous treatment(s), Revuforj may be a treatment option for you. Revuforj is an oral, targeted medication that works differently than chemotherapy.
Revuforj works by targeting
menin
to disrupt the
protein interactions
that are responsible for driving the growth of leukemia cells in people who have AML or ALL with a KMT2A translocation.
How acute leukemia with a KMT2A translocation works:
Interactions between menin and certain proteins trigger the production of leukemia cells
These leukemia cells grow and multiply quickly and stop from turning into normal blood cells
Leukemia cells continue to multiply and take over the bone marrow, causing acute leukemia
How Revuforj works:
Revuforj targets and directly binds to menin to block the source of what drives your specific type of acute leukemia
Disrupting those menin interactions can help cells start to turn into normal blood cells
Without as many leukemia cells, there’s space in the bone marrow for healthy blood cells to grow
How acute leukemia with a KMT2A translocation works:
Interactions between menin and certain proteins trigger the production of leukemia cells
These leukemia cells grow and multiply quickly and stop from turning into normal blood cells
Leukemia cells continue to multiply and take over the bone marrow, causing acute leukemia
How Revuforj works:
Revuforj targets and directly binds to menin to block the source of what drives your specific type of acute leukemia
Disrupting those menin interactions can help cells start to turn into normal blood cells
Without as many leukemia cells, there’s space in the bone marrow for healthy blood cells to grow
Revuforj will not work for everyone. Individual results may vary.
